Abstract

Background Crohn’s disease is the most frequent inflammatory bowel disease. The use of the TNFa inhibitors has completely revolutionized the therapeutical management of recalcitrant cases of Crohn’s disease [1]. Unfortunately many side effects have been described in association with the use of the TNFa inhibitors[2]. The development of antinuclear antibodies is frequently described but is not always associated with a pathological condition [3]. The occurrence of lupus like syndrome after initiating the TNFa inhibitors therapy is rare and estimated with a prevalence of 0,5% to 1% [4]. We described a case of a lupus-like syndrome induced by the infliximab in a patient treated for Crohn’s disease. Case report We report a case of a young woman suffering from Crohn’s disease since 2001. She was treated by infliximab at the dose of 5 mg/kg every 8 weeks since 2009. She developed in 2011 an extensive lichenoid eruption in her arms and legs [Figure 1]. She developed at the same time an important anemia. Her blood analyses showed the presence of antinuclear antibodies at a title of 1/640 and anti double strand DNA at a title of 25 UI that were negative before the initiation of the infliximab. Skin biopsies were performed and showed an histological picture of lupus. Six weeks after the withdrawal of the infliximab therapy the skin lesions were completely healed

Highlights

  • Crohn’s disease is the most frequent inflammatory bowel disease

  • Case report We report a case of a young woman suffering from Crohn’s disease since 2001

  • She was treated by infliximab at the dose of 5 mg/kg every 8 weeks since 2009. She developed in 2011 an extensive lichenoid eruption in her arms and legs [Figure 1]

Read more

Summary

Introduction

Crohn’s disease is the most frequent inflammatory bowel disease. The use of the TNFa inhibitors has completely revolutionized the therapeutical management of recalcitrant cases of Crohn’s disease [1]. Case report We report a case of a young woman suffering from Crohn’s disease since 2001. She was treated by infliximab at the dose of 5 mg/kg every 8 weeks since 2009.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call